The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim am Rhein. From its beginnings in 1885 when it employed just 28 people in Nieder-Ingelheim, the company has since become a global enterprise.

As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.

Innovations Delivering Real Value
An evolving portfolio of products and services translating innovations into solutions for a world of fast-paced change and increased challenges.

Vaccine technologies
that keep animals healthier and businesses running more efficiently.

Parasiticides and therapeutics
that are both effective and easier to administer, whether to finicky pets or large herds of livestock.

Digital tools and technologies
that help everyone work smarter and faster.

Ingelvac - Model HP-1 - Haemophilus Parasuis Bacteria Brochure